ReviewPain and therapy2026
Neuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review.
Review in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neuropathic pain (NP) has attracted growing attention in recent years; however, its pathogenesis remains incompletely understood, and therapeutic options remain limited. Neuromodulation techniques have demonstrated considerable promise in managing NP, offering advantages including noninvasiveness, minimal discomfort, and precise anatomical targeting. Nevertheless, therapeutic parameters have yet to be standardized as a result of variability across multiple factors such as modality type, stimulation site, and treatment duration. Microglia, as the resident immune cells of the central nervous system, play a pivotal role in the development and maintenance of NP. Following nerve injury, microglia become activated and release various inflammatory mediators and signaling molecules that modulate pain transmission pathways. Importantly, emerging evidence indicates that neuromodulation can regulate microglial activation states and associated inflammatory cascades through either indirect or direct pathways. Indirect mechanisms involve modulating neuronal activity and downstream signaling, thereby influencing microglial functional phenotypes. Direct mechanisms act via microglia-specific properties such as electrophysiological sensitivity, receptor expression, or local field potential interactions. This review synthesizes current evidence on the mechanisms and recent advances in microglia-targeted neuromodulation strategies for NP relief, distinguishing between preclinical and clinically validated findings, and aiming to provide a theoretical foundation for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.